🇺🇸 FDA
Patent

US 7611728

Osmotic delivery of therapeutic compounds by solubility enhancement

granted A61KA61K9/0004A61P

Quick answer

US patent 7611728 (Osmotic delivery of therapeutic compounds by solubility enhancement) held by Supernus Pharmaceuticals, Inc. expires Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Supernus Pharmaceuticals, Inc.
Grant date
Tue Nov 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K9/0004, A61P, A61P3/10